Healius (ASX: HLS) — Perfil da empresa, notícias e dados financeiros
Healius Limited provides diverse medical services including pathology and imaging across Australia.
Healius
Healius is a provider of pathology and diagnostic imaging services operating across Australia. The company offers a comprehensive range of medical laboratory testing, specialty diagnostics, genomic services, and diagnostic imaging including MRI, CT, ultrasound, and digital X-ray. Through clinical brands such as Laverty Pathology, QML Pathology, Western Diagnostic Pathology, and Lumus Imaging, Healius supports general practitioners, medical specialists, hospitals, and corporate clients. It operates thousands of sample collection centres and diagnostic clinics nationwide, delivering critical health data that supports disease diagnosis, treatment planning, and preventive care across metropolitan, regional, and remote communities.
Resumo
Operações
Produtos e/ou serviços de Healius
- Pathology Services: Operates a vast network of medical laboratories and over 2,000 collection centres across Australia under regional brands including Laverty, QML, Western Diagnostic, and Abbott Pathology, delivering comprehensive diagnostic testing for clinical care.
- Diagnostic Imaging Services: Delivers medical imaging solutions through Lumus Imaging, providing X-ray, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), mammography, and nuclear medicine services across community clinics, medical centres, and hospital sites nationwide.
- Genomic Diagnostic Testing: Offers specialized genomic and pharmacogenomic (PGx) testing solutions that evaluate genetic factors to guide personalized patient treatment, targeted therapies, and precision medicine strategies across clinical specialties throughout Australia.
- Specialty & Commercial Pathology: Provides targeted anatomical pathology, veterinary diagnostics, dermatopathology, and corporate health testing services, supporting specialized healthcare practitioners, commercial clients, research organizations, and public health initiatives across Australian states and territories.
- Digital Healthcare Tools: Develops digital access portals and AI-enabled diagnostic decision-support tools that streamline pathology test ordering, expedite results delivery for referring practitioners, and enhance direct consumer engagement with clinical diagnostic healthcare information.
- Diagnostic Collection & Logistics: Maintains an extensive national sample collection network and dedicated medical logistics infrastructure to facilitate rapid specimen transport, timely laboratory processing, and high-volume diagnostic workflows across metropolitan, regional, and rural health networks.
equipe executiva do Healius
- Paul D. AndersonMD, CEO & Director
- Andrew ThomsonCFO & Company Secretary
- Puneet NagiChief Operating Officer
- Prasad AravGroup Executive of Digital & Technology and Strategy
- Sharon NgHead of FP&A and Investor Relations
- Kylie BrownGroup General Counsel, Company Secretary & Chief Risk Officer
- Paula BaylissGroup Executive of People & Culture
- John McKechnieAdvisor
- Phil LucasChief Executive of Lumus Imaging
- Ian McphanChief Operating Officer of Healius Pathology
Comunicados recentes
O que a Healius (HLS) comunicou ao mercado, do mais recente para o mais antigo.
- Becoming a substantial holder from MUFG
- Becoming a substantial holder
- Ceasing to be a substantial holder from MUFG
- Ceasing to be a substantial holder
- Ceasing to be a substantial holder
Histórico de dividendos
Dividendos por ação pagos pela Healius, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2025 | — | A$0.4130 | — | A$0.4130 |
| FY2023 | A$0.0555 | — | — | A$0.0555 |
| FY2022 | A$0.0625 | A$0.0926 | — | A$0.1550 |
| FY2021 | — | A$0.0602 | — | A$0.0602 |
| FY2020 | A$0.0315 | A$0.0241 | — | A$0.0555 |
Principais indicadores financeiros
Resultados divulgados pela Healius, em AUD.
- Cap. de mercado
- 360,9 mi
- Receita (TTM)
- 1,4 bi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- -30.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,4 bi | 30,2 mi | -415,6 mi | |
| 1,3 bi | 200 mil | -151,2 mi | |
| 1,7 bi | 65,5 mi | -645,8 mi | |
| 1,7 bi | 98,1 mi | -367,8 mi |